Hyperion DeFi (NASDAQ:HYPD) Posts Earnings Results

Hyperion DeFi (NASDAQ:HYPD) released its quarterly earnings results on Thursday. The company reported ($7.76) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.50 million for the quarter.

Hyperion DeFi Price Performance

HYPD traded down $0.06 during trading on Thursday, hitting $3.65. 93,295 shares of the stock traded hands, compared to its average volume of 383,091. The business has a 50 day moving average price of $3.46 and a 200 day moving average price of $5.33. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.25 and a quick ratio of 2.25. Hyperion DeFi has a twelve month low of $0.85 and a twelve month high of $17.18. The company has a market cap of $29.78 million, a price-to-earnings ratio of -0.90 and a beta of 2.74.

Wall Street Analyst Weigh In

HYPD has been the topic of a number of recent research reports. Zacks Research upgraded Hyperion DeFi to a “hold” rating in a research note on Monday, December 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Thursday, January 22nd. Chardan Capital set a $7.75 price target on Hyperion DeFi and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Finally, Cantor Fitzgerald initiated coverage on Hyperion DeFi in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price target for the company. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.88.

Insiders Place Their Bets

In other Hyperion DeFi news, CFO David R. Knox purchased 27,950 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The shares were bought at an average price of $3.59 per share, for a total transaction of $100,340.50. Following the purchase, the chief financial officer owned 327,950 shares in the company, valued at approximately $1,177,340.50. This trade represents a 9.32% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ellen R. Strahlman purchased 11,856 shares of the stock in a transaction dated Monday, December 29th. The shares were acquired at an average cost of $3.61 per share, with a total value of $42,800.16. Following the acquisition, the director directly owned 34,869 shares in the company, valued at $125,877.09. This represents a 51.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 58,830 shares of company stock worth $213,424. Company insiders own 10.86% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in shares of Hyperion DeFi in the fourth quarter worth about $663,000. Jane Street Group LLC bought a new stake in shares of Hyperion DeFi during the 4th quarter valued at approximately $493,000. Focus Partners Advisor Solutions LLC acquired a new position in Hyperion DeFi during the 4th quarter worth approximately $221,000. Geode Capital Management LLC acquired a new position in Hyperion DeFi during the 4th quarter worth approximately $214,000. Finally, Investment House LLC bought a new position in Hyperion DeFi in the 4th quarter valued at approximately $166,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.